Insulin resistance and lipid profile in women with polycystic appearing ovaries: implications with regard to polycystic ovary syndrome

References

• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800
   PubMed Web of Science ®Google Scholar
• Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, et al., eds. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scientific Publications, 1992:377–84
   Google Scholar
• Carmina E, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertil Steril 1999;71:319–22
   PubMed Web of Science ®Google Scholar
• Oberfield SE. Metabolic lessons from the study of young adolescents with polycystic ovary syndrome — is insulin indeed, the culprit? (editorial) J Gun Endocrinol Metab 2000;85;3520–5
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome. N Engl J Med 1995;3:853–61
   Google Scholar
• Rajkhowa M, Glass MR, Rutherford AJ, et al. Polycystic ovary syndrome: a risk factor for cardio-vascular disease. BrJ Obstet Gynaecol 2000;107:11–18
   Google Scholar
• Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Gun Endocrinol Metab 1980;50: 113–16
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38: 1165–74
   PubMed Web of Science ®Google Scholar
• Chang RJ, Nakamura RM, Judd HL, et al. Insulin resistance in nonobese patients with polycystic ovarian disease. J Gun Endocrinol Metab 1983;57: 356–9
   PubMed Web of Science ®Google Scholar
• DunaifA, GrafM, Mandeli J, etal. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance and/or hyper-insulinemia. J Gun Endocrinol Metab 1987;65:499–507
   Google Scholar
• Conway GS, Agrawal R, Betteridge DJ, et al. Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin Endocrinol (04 1992;37:119–25
   PubMed Web of Science ®Google Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 2000;15:1266–74
   Google Scholar
• Kelly CJG, Connell JMC, Cameron IT, et al. The long-term health consequences of polycystic ovary syndrome. Br J Obstet Gynaecol 2000;107:1327–38
   Google Scholar
• Rajkhowa M, Neary RH, Kumpatla P, et al. Altered composition of high-density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:3389–94
   PubMed Web of Science ®Google Scholar
• Wild RA, Painter PC, Coulson PB, et al. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Gun Endocrinol Metab 1985;61:946–51
   PubMed Web of Science ®Google Scholar
• Loucks TL, Talbott EO, McHugh KP, et al. Do polycystic-appearing ovaries affect the risk of cardio-vascular disease among women with polycystic ovary syndrome? Fertil Steril 2000;74:547–52
   PubMed Web of Science ®Google Scholar
• Gupta S. Polycystic ovarian syndrome: is community care appropriate? Int J Clin Pract 1999;53:359–62
   Google Scholar
• Holte J, Bergh T, Berne C, et al. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (04 1994; 41:463–71
   PubMed Web of Science ®Google Scholar
• Graf MJ, Richards CJ, Brown V, et al. The independ-ent effects of hyperandrogenaemia, hyperinsulinaemia and obesity on lipid and lipoprotein profiles in women. Clin Endocrinol (04) 1990;33: 119–31
   Google Scholar
• Slowinska-Srzednicka J, Zgliczynski S, Wierzbicki M, etal. The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome.JEndocrinol Invest 1991;14:569–75
   Google Scholar
• Gennarelli G, Holte J, Berglund L, et al. Prediction models for insulin resistance in the polycystic ovary syndrome. Hum Reprod 2000;15:2098–102
   PubMed Web of Science ®Google Scholar
• Talbott EO, Zborowski JV, Sutton-Tyrell K, et al. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28:111–33
   PubMed Web of Science ®Google Scholar
• Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989–93
   PubMed Web of Science ®Google Scholar
• Carmina E, Wong L, Chang L, et al. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod 1997;12:905–9
   PubMed Web of Science ®Google Scholar
• Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 1986;293:355–9
   Google Scholar
• Katz A, Nambi SS, Mather K, et al. Quantitative Insulin Sensitivity Check Index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402–10
   PubMed Web of Science ®Google Scholar
• Bonora E, Targher G, Alberiche M, etal. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 2000;23:57–63
   PubMed Web of Science ®Google Scholar
• Koivunen R, Laatikainen T, Tomas C, et al. The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand 1999;78:137–41
   PubMed Web of Science ®Google Scholar
• Polson DW, Wadsworth J, Adams J, et al. Polycystic ovaries — common finding in normal women. Lancet 1988;1:870–2
   PubMed Web of Science ®Google Scholar
• Norman RJ, Hague WM, Masters SC, et al. Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. Hum Reprod 1995;10:2258–61
   PubMedGoogle Scholar
• Van Santbrink EJP, Hop WC, Fauser BCJM. Classification of normogonadotropic infertility: poly-cystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil Steril 1997;67:452–8
   Google Scholar
• Pirwany IR, Fleming R, Greer IA, et al. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Gun Endocrinol (04 2001;54:447–53
   Google Scholar
• Velazquez ME, Bellabarba GA, Mendoza S, et al. Postprandial triglyceride response in patients with polycystic ovary syndrome: relationship with waist-to-hip ratio and insulin. Fertil Steril 2000;74:1159–63
   PubMed Web of Science ®Google Scholar
• Martin BC, Warram JH, Krolewski AS, etal. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992;340:925–9
   PubMed Web of Science ®Google Scholar
• Yip J, Facchini F, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Gun Endocrinol Metab 1998; 88:2773–6
   Google Scholar
• Rajkhowa M, Bicknell J, Jones M, et al. Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia. Feral Steril 1994;61:605–12
   PubMed Web of Science ®Google Scholar
• Arthur LSC, Selvakumar R, Seshadri M, et al. Hyper-insulinemia in polycystic ovary disease. J Reprod Med 1999;44:783–7
   Google Scholar
• Haffner SM, Katz MS, Stern MP, et al. The relation-ship of sex hormones to hyperinsulinemia and hyperglycemia. Metabolism 1988;37:683–8
   PubMed Web of Science ®Google Scholar
• Acien P, Quereda F, Matallin P, et al. Insulin, androgens and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999;72:32–40
   PubMed Web of Science ®Google Scholar
• Anttila L, Ding Y-Q, Ruutiainen K, et al. Clinical features and circulating gonadotropin, insulin and androgen interactions in women with polycystic ovarian disease. Feral Steril 1991;55:1057–61
   Google Scholar
• Sampson M, Kong C, Patel A, etal. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without polycystic ovary syndrome. Clin Endocrinol (04 1996;45:623–9
   PubMed Web of Science ®Google Scholar
• Hopkinson ZEC, Sattar N, Fleming R, et al. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. Br Med J 1998;317:329–32
   PubMed Web of Science ®Google Scholar
• Jensen J. Effects of sex steroids on serum lipids and lipoproteins. Bailliere's Clin Obstet Gynecol 1991; 5:867–87
   PubMedGoogle Scholar
• Mahabeer S, Naidoo C, Norman RJ, et al. Metabolic profiles and lipoprotein lipid concentrations in non-obese and obese patients with polycystic ovarian disease. Harm Metab Res 1990;22:537–40
   Google Scholar
• Frayn KN. Insulin resistance and lipid metabolism. Curr Opin Lipidol 1993;4:197–204
   Google Scholar
• Paradisi G, Steinberg HO, Hempffing A, et al. Polycystic ovary syndrome is associated with endo-thelial dysfunction. Circulation 2001;103:1410–15
   PubMed Web of Science ®Google Scholar